• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

过渡性呼吸困难指数的最小临床重要差异是总分1分。

The MCID of the transition dyspnea index is a total score of one unit.

作者信息

Mahler Donald A, Witek Theodore J

机构信息

Dartmouth Medical School, Lebanon, New Hampshire 03656-0001, USA.

出版信息

COPD. 2005 Mar;2(1):99-103. doi: 10.1081/copd-200050666.

DOI:10.1081/copd-200050666
PMID:17136969
Abstract

The Baseline (BDI) and Transition (TDI) Dyspnea Indexes provide interview-based measurements of breathlessness related to activities of daily living. The BDI is a discriminative instrument that includes specific criteria for each of three components at a single point in time. The TDI is an evaluative instrument that includes specific criteria for each of three components to measure changes from a baseline state. Observational studies have shown that patients with COPD generally experience a gradual progression of breathing difficulty as measured by the TDI over time. Randomized controlled trials have demonstrated excellent measurement characteristics of the TDI; these include responsiveness (ability to detect change) and construct validity (a change in the TDI correlates with changes in other variables). Supporting evidence for one unit as the minimal clinically important difference (MCID) of the TDI is based on: expert preference; use of the physician's global evaluation score as an anchor; and distribution estimates (standard error of measurement and 0.5 of the standard deviation). As an alternative to the interview process, self-administered computerized (SAC) versions of the BDI/TDI have been developed to provide direct patient-reported ratings of dyspnea. To further establish the MCID of the interview-administered and/or the SAC TDI, we recommend that a patient's report of global ratings of change by used as an independent standard or anchor.

摘要

基线(BDI)和过渡(TDI)呼吸困难指数提供了基于访谈的与日常生活活动相关的呼吸急促测量方法。BDI是一种判别工具,在单个时间点对三个组成部分中的每一个都包含特定标准。TDI是一种评估工具,对三个组成部分中的每一个都包含特定标准,以测量相对于基线状态的变化。观察性研究表明,慢性阻塞性肺疾病(COPD)患者随着时间推移,通过TDI测量的呼吸困难通常会逐渐加重。随机对照试验已证明TDI具有出色的测量特性;这些特性包括反应性(检测变化的能力)和结构效度(TDI的变化与其他变量的变化相关)。将一个单位作为TDI最小临床重要差异(MCID)的支持证据基于:专家偏好;将医生的整体评估评分用作对照;以及分布估计(测量标准误差和标准差的0.5)。作为访谈过程的替代方法,已开发出BDI/TDI的自我管理计算机化(SAC)版本,以提供患者直接报告的呼吸困难评分。为了进一步确定访谈管理的和/或SAC TDI的MCID,我们建议将患者报告的整体变化评分用作独立标准或对照。

相似文献

1
The MCID of the transition dyspnea index is a total score of one unit.过渡性呼吸困难指数的最小临床重要差异是总分1分。
COPD. 2005 Mar;2(1):99-103. doi: 10.1081/copd-200050666.
2
Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes.基线和过渡性呼吸困难指数的自我管理计算机化版本的有效性和反应性。
Chest. 2007 Oct;132(4):1283-90. doi: 10.1378/chest.07-0703. Epub 2007 Jul 23.
3
[Validation study of the BDI/TDI scores in chronic obstructive pulmonary disease].[慢性阻塞性肺疾病中BDI/TDI评分的验证研究]
Rev Mal Respir. 2009 Sep;26(7):735-43. doi: 10.1016/s0761-8425(09)72424-6.
4
Validity of a Self-administered Questionnaire Version of the Transition Dyspnea Index in Patients with COPD.慢性阻塞性肺疾病患者中自填式过渡性呼吸困难指数问卷的效度
COPD. 2017 Feb;14(1):66-71. doi: 10.1080/15412555.2016.1246522. Epub 2016 Nov 14.
5
Meaningful effect size and patterns of response of the transition dyspnea index.过渡性呼吸困难指数的有意义效应大小及反应模式。
J Clin Epidemiol. 2003 Mar;56(3):248-55. doi: 10.1016/s0895-4356(02)00589-9.
6
Minimal important difference of the transition dyspnoea index in a multinational clinical trial.一项跨国临床试验中过渡性呼吸困难指数的最小重要差异
Eur Respir J. 2003 Feb;21(2):267-72. doi: 10.1183/09031936.03.00068503a.
7
A meta-analysis of four randomized clinical trials to confirm the reliability and responsiveness of the Shortness of Breath with Daily Activities (SOBDA) questionnaire in chronic obstructive pulmonary disease.一项对四项随机临床试验的荟萃分析,以证实日常活动气短(SOBDA)问卷在慢性阻塞性肺疾病中的可靠性和反应性。
Health Qual Life Outcomes. 2015 Oct 31;13:177. doi: 10.1186/s12955-015-0369-3.
8
[Ways to quantify dyspnea severity. Part I. Baseline Dyspnea Index (BDI), Transition Dyspnea Index (TDI)].量化呼吸困难严重程度的方法。第一部分。基线呼吸困难指数(BDI)、过渡性呼吸困难指数(TDI)。
Pneumologia. 2006 Apr-Jun;55(2):58-63.
9
Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI).使用基础呼吸困难指数(BDI)和过渡呼吸困难指数(TDI)评估结节病患者的呼吸困难。
Respir Med. 2022 Jan;191:106436. doi: 10.1016/j.rmed.2021.106436. Epub 2021 May 4.
10
Elastic tape reduces dyspnea and improves health status in the short term in nonobese COPD males: A randomized controlled trial.弹性胶带在短期内可减少非肥胖 COPD 男性的呼吸困难并改善健康状况:一项随机对照试验。
Respir Med. 2024 Jan;221:107459. doi: 10.1016/j.rmed.2023.107459. Epub 2023 Nov 8.

引用本文的文献

1
The effectiveness and value of ensifentrine for the treatment of chronic obstructive pulmonary disease.恩昔芬净治疗慢性阻塞性肺疾病的有效性和价值。
J Manag Care Spec Pharm. 2024 Nov;30(11):1338-1342. doi: 10.18553/jmcp.2024.30.11.1338.
2
Effects of inspiratory muscle training on exertional breathlessness in patients with unilateral diaphragm dysfunction: a randomised trial.吸气肌训练对单侧膈肌功能障碍患者运动性呼吸困难的影响:一项随机试验。
ERJ Open Res. 2023 Oct 2;9(5). doi: 10.1183/23120541.00300-2023. eCollection 2023 Sep.
3
Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease.
奈诺沙星在改善慢性阻塞性肺疾病急性加重患者的症状和延长下次加重时间方面优于莫西沙星。
Sci Rep. 2023 Oct 7;13(1):16954. doi: 10.1038/s41598-023-44188-2.
4
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?EMAX 试验关于慢性阻塞性肺疾病长效支气管扩张的发现如何应用于初级保健环境?
Chron Respir Dis. 2023 Jan-Dec;20:14799731231202257. doi: 10.1177/14799731231202257.
5
Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline.慢性呼吸疾病成人的肺康复:美国胸科学会临床实践指南
Am J Respir Crit Care Med. 2023 Aug 15;208(4):e7-e26. doi: 10.1164/rccm.202306-1066ST.
6
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.恩塞福林作为一种新型吸入疗法用于 COPD 患者的治疗。
Int J Chron Obstruct Pulmon Dis. 2023 Jul 28;18:1611-1622. doi: 10.2147/COPD.S413436. eCollection 2023.
7
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).依诺司特,一种新型磷酸二酯酶 3 和 4 抑制剂,用于治疗慢性阻塞性肺疾病:随机、双盲、安慰剂对照、多中心 III 期临床试验(ENHANCE 试验)。
Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC.
8
Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary disease (COPD).吸气肌训练,联合或不联合肺康复治疗,用于慢性阻塞性肺疾病(COPD)。
Cochrane Database Syst Rev. 2023 Jan 6;1(1):CD013778. doi: 10.1002/14651858.CD013778.pub2.
9
Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function.暴露于烟草环境下的症状稳定的肺功能正常人群中使用支气管扩张剂。
N Engl J Med. 2022 Sep 29;387(13):1173-1184. doi: 10.1056/NEJMoa2204752. Epub 2022 Sep 4.
10
Discriminative Accuracy of Chronic Obstructive Pulmonary Disease Screening Instruments in 3 Low- and Middle-Income Country Settings.在 3 个中低收入国家环境下,慢性阻塞性肺疾病筛查工具的鉴别准确性。
JAMA. 2022 Jan 11;327(2):151-160. doi: 10.1001/jama.2021.23065.